Disc Medicine, Inc. (IRON)
IRON moved a median of +0.09% 30 minutes after news, and +0.09% by the close. How IRON actually reacts to news — the realized, point-in-time move the market made, measured across 745 labeled events over the last three years with zero look-ahead.
IRON’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.02% | 53% | 735 |
| 30-min | +0.09% | 53% | 741 |
| 60-min | -0.14% | 47% | 741 |
| to close | +0.09% | 52% | 740 |
| Middle 50% of IRON reactions | -0.95% to +1.08% |
|---|---|
| Median reaction (30-min) | +0.09% |
| Measured reactions | 745 |
Half of all Disc Medicine, Inc. news events land between -0.95% and +1.08% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IRON reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 19 | -0.81% | 21% | -2.20% |
| Rating reiterations | 106 | -0.16% | 46% | +0.07% |
| Price-target raises | 19 | -0.51% | 32% | +0.67% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how IRON ranks against every other measured name →
That’s how IRON usually reacts — get an email when it moves on news →Email me when IRON moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IRON's baseline. Nothing else.
Recent IRON events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | — | — | |
| Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) | Press release | GlobeNewswire | +3.96% | +8.57% | |
| Form 8-K Disc Medicine, Inc. For: Oct 19 | SEC filing · Form 8-K | SEC EDGAR | +3.96% | +8.57% | |
| Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) | Press release | GlobeNewswire | +3.96% | +8.57% | |
| Form 8-K Disc Medicine, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -2.31% | |
| Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting | Press release | GlobeNewswire | -0.03% | -2.31% | |
| Disc Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.63% | +0.77% | |
| Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting | Press release | GlobeNewswire | -0.65% | +0.14% | |
| Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.01% | +6.79% | |
| Form 10-Q Disc Medicine, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.01% | +6.79% | |
| Form 8-K Disc Medicine, Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | +6.79% | |
| Form 8-K Disc Medicine, Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | +2.80% | |
| Form 8-K Disc Medicine, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +0.40% | -0.33% | |
| Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting | Press release | GlobeNewswire | -0.71% | -0.19% | |
| Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Press release | GlobeNewswire | +0.23% | +1.89% | |
| Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | Press release | GlobeNewswire | -0.96% | -4.36% | |
| Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients | Press release | GlobeNewswire | -1.96% | +5.11% | |
| Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress | Press release | GlobeNewswire | +2.92% | -0.49% | |
| Disc Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +3.17% | +0.32% | |
| Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.22% | -0.60% | |
| Form 10-Q Disc Medicine, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.22% | -0.60% | |
| Form 8-K Disc Medicine, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +1.22% | -0.60% | |
| Form ARS Disc Medicine, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.58% | -0.92% | |
| Form DEF 14A Disc Medicine, Inc. For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | -0.58% | -0.92% | |
| Form DEFA14A Disc Medicine, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.58% | -0.92% | |
| Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting | Press release | GlobeNewswire | -0.54% | -1.50% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +1.52% | +1.15% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +1.52% | +1.15% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.08% | -0.41% | |
| Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -0.93% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.19% | -1.48% | |
| Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria | Press release | GlobeNewswire | -1.20% | -3.39% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.01% | +1.21% | |
| Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.56% | -0.94% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.25% | -0.79% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.22% | -1.93% | |
| Form 8-K Disc Medicine, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | +2.37% | |
| Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.56% | +0.61% | |
| Form 10-K Disc Medicine, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.56% | +0.61% | |
| Form 8-K Disc Medicine, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | +0.61% | |
| Form S-8 Disc Medicine, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.56% | +0.61% | |
| Disc Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.79% | +2.32% | |
| Form 8-K Disc Medicine, Inc. For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +11.39% | +17.78% | |
| Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP | Press release | GlobeNewswire | +1.17% | +14.63% | |
| Form 8-K Disc Medicine, Inc. For: Feb 13 | SEC filing · Form 8-K | SEC EDGAR | +11.39% | +17.78% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.27% | +0.13% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.04% | +1.21% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.84% | -7.84% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.21% | -5.70% | |
| Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.80% | +2.52% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IRON section they belong to.
Where else IRON is measured.
IRON earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Disc Medicine, Inc.'s median reaction calculated?
Every labeled IRON news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 745 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of IRON's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IRON's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.